Compare 10X Genomics Inc (TXG) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
10X Genomics Inc vs Williams-Sonoma, Inc. — how do they compare? 10X Genomics Inc trades at $58.03 (market cap $7.61B), while Williams-Sonoma, Inc. trades at $247.49 (market cap $29.51B). The key difference: Williams-Sonoma, Inc. is far larger — about 3.9× 10X Genomics Inc's market cap, and Williams-Sonoma, Inc. pays a 1.21% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| TXG | WSM | |
|---|---|---|
Market Cap | $7.61B | $29.51B |
Sector | Health | Consumer Cyclical |
52-Week High | $58.57 | $251.81 |
52-Week Low | $11.34 | $168.64 |
Enterprise Value | $7.14B | $30.35B |
Dividend Yield | — | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TXG trades at $58.57, up 12.57% in 24 hours, reflecting strong momentum. The stock is technically bullish with moving averages supporting the uptrend, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and revenue growth, yet remains unprofitable with a negative net income margin. Recent news highlights collaborations and acquisitions expanding its genomic capabilities.
Outlook is mixed; analyst consensus is neutral with a $46 price target below current levels, indicating caution despite recent beats. Key risks include sustained losses and competitive pressures, but operational cash flow growth and strategic expansions offer potential upside for patient investors focused on long-term biotech innovation.
Williams-Sonoma (WSM) trades at $250.82, down 0.39% on the day, with strong profitability metrics including a 13.81% net income margin and 54.01% ROE. The stock shows a bullish technical trend, supported by moving averages, but RSI levels indicate overbought conditions. Recent earnings beats and a solid dividend history highlight operational strength, though valuation ratios like P/E of 28.09 suggest premium pricing. News coverage remains active, focusing on earnings potential and competitive positioning in the home furnishings sector.
WSM presents a mixed outlook: robust fundamentals and consistent earnings beats support upside, but high valuation and technical overbought signals pose near-term risks. Investor sentiment is cautiously optimistic, with a Moderate Buy analyst consensus and a $231.10 price target slightly below current levels. Key risks include consumer discretionary volatility and competitive pressures, while institutional interest and dividend payments offer stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
